Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study

NEXT STORY
Sun BioPharma, Inc. Provides Business Update and Reports Q2 2020 Financial Results
PREV STORY
BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the U.S.
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

New ARAMIS Phase III data to be presented at ASCO 2020: Nubeqa® (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer

author_avatar
NASDAQ Market News

Todos Medical Enters Into Distribution Partnership with Osang Healthcare for the GeneFinder Plus™ COVID-19 Plus RealAMP Kit in the United States

author_avatar
NASDAQ Market News

Intra-Cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update

author_avatar
NASDAQ Market News